Malta - angličtina - Medicines Authority

janssen-cilag international nv turnhoutsewes 30, b-2340 beerse, belgium - galantamine - film-coated tablet - galantamine - psychoanaleptics

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - memantine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - memantine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - memantine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - memantine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride -

Spojené štáty - angličtina - NLM (National Library of Medicine)

aurobindo pharma limited - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 5 mg - memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population